Withdrawals due to adverse events · people with eczema
It is very uncertain whether topical steroid plus topical antibiotic changes adverse events requiring withdrawal from treatment compared with topical steroid (very low certainty).
1 finding from 1 review
Minor adverse events not leading to withdrawal of treatment · people with eczema
It is very uncertain whether topical steroid plus topical antibiotic changes minor adverse events not requiring withdrawal from treatment compared with topical steroid (very low certainty).
1 finding from 1 review
Microbiology Emergence of resistant organisms · people with eczema
1 finding from 1 review
Global change in composite ratings scale EASI ranges from 0 to 72, objective SCORAD ranges from 0 to 83 and SCORAD ranges from 0 to 108, with higher values indicating greater severity. · people with eczema
1 finding from 1 review
No of participants in whom S. aureus was isolated · people with eczema
Topical steroid plus topical antibiotic probably leads to lower no of participants in whom S. aureus was isolated compared with topical steroid (moderate certainty).
1 finding from 1 review
Global outcome (good or excellent improvement in symptoms or signs, or both) · people with atopic dermatitis
Oral antibiotic showed no clear difference in global outcome (good or excellent improvement in symptoms or signs,… compared with placebo (low certainty).
1 finding from 1 review
Change from baseline in quality of life IDQoL ranges from 0 to 30 with higher values indicating more impaired quality of life. · people with atopic dermatitis
1 finding from 1 review
Primary: investigator‐rated good/excellent control of symptoms · participants with moderate to severe hand eczema
Corticosteroid creams/ointments: clobetasol propionate foam showed no clear difference in primary: investigator‐rated good/excellent control of symptoms compared with vehicle foam (moderate certainty).
1 finding from 1 review
Secondary: investigator‐rated reduction in severity ‐ Not measured · people (all patch‐tested) with hand eczema > 6 months that had cleared upon daily treatment for a maximum of 9 weeks with mometasone…
The review found no eligible studies for this question.
1 finding from 1 review
Primary: investigator‐rated good/excellent control of symptoms · people with hand eczema unresponsive to clobetasol propionate
Irradiation with UV light: local narrow‐band UVB showed no clear difference in primary: investigator‐rated good/excellent control of symptoms compared with local PUVA (moderate certainty).
1 finding from 1 review
Primary: participant‐rated good/excellent control of symptoms Not measured · people with hand eczema unresponsive to clobetasol propionate
The review found no eligible studies for this question.
1 finding from 1 review
Primary: adverse events ‐ reported adverse events, mainly erythema · people with hand eczema unresponsive to clobetasol propionate
Irradiation with UV light: local narrow‐band UVB probably leads to higher primary: adverse events ‐ reported adverse events, mainly erythema compared with local PUVA (moderate certainty).
1 finding from 1 review
Secondary: investigator‐rated reduction in severity in mTLSSd · people with hand eczema unresponsive to clobetasol propionate
1 finding from 1 review
Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe chronic relapsing dyshidrotic eczema on hands
The review found no eligible studies for this question.
1 finding from 1 review
Primary: participant‐rated good/excellent control of symptoms Not measured · people with moderate to severe chronic relapsing dyshidrotic eczema on hands
The review found no eligible studies for this question.
1 finding from 1 review
Primary outcome 3: Adverse events · people with moderate to severe chronic relapsing dyshidrotic eczema on hands
1 finding from 1 review
Secondary: investigator‐rated reduction in severity ‐ DASIb · people with moderate to severe chronic relapsing dyshidrotic eczema on hands
1 finding from 1 review
Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
Topical calcineurin inhibitors: tacrolimus 0.1% ointment probably leads to higher primary: investigator‐rated good/excellent control of symptoms compared with vehicle (moderate certainty).
1 finding from 1 review
Primary: participant‐rated good/excellent control of symptoms · participants with moderate to severe hand eczema
Corticosteroid creams/ointments: clobetasol propionate foam probably leads to higher primary: participants with self‐rated good/excellent control of… compared with vehicle foam (moderate certainty).
1 finding from 1 review
Primary: participant‐rated good/excellent control of symptoms Not measured · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
The review found no eligible studies for this question.
1 finding from 1 review